{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T18:02:19Z","timestamp":1781287339652,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Chronic kidney disease (CKD) is highly prevalent in patients with coronary artery disease (CAD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The outcome following revascularization using contemporary technologies (new-generation abluminal sirolimus-eluting stents with thin struts) in patients with CKD (i.e., glomerular filtration rate of\u2009&lt;\u200960\u00a0mL\/min\/1.73m<jats:sup>2<\/jats:sup>) and in patients with hemodialysis (HD) is unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>e-Ultimaster is a prospective, single-arm, multi-center registry with clinical follow-up at 3 months and 1\u00a0year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 19,475 patients were enrolled, including 1466 patients with CKD, with 167 undergoing HD. Patients with CKD had a higher prevalence of overall comorbidities, multiple\/small vessel disease (\u2264\u20092.75\u00a0mm), bifurcation lesions, and more often left main artery treatments (all<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) when compared with patients with normal renal function (reference). CKD patients had a higher risk of target lesion failure (unadjusted OR, 2.51 [95% CI 2.04\u20133.08]), target vessel failure (OR, 2.44 [95% CI 2.01\u20132.96]), patient-oriented composite end point (OR, 2.19 [95% CI 1.87\u20132.56]), and major adverse cardiovascular events (OR, 2.34 [95% CI 1.93\u20132.83,<jats:italic>p<\/jats:italic>for all\u2009&lt;\u20090.0001]) as reference. The rates of target lesion revascularization (OR, 1.17 [95% CI 0.79\u20131.73],<jats:italic>p<\/jats:italic>\u2009=\u20090.44) were not different. Bleeding complications were more frequently observed in CKD than in the reference (all<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this worldwide registry, CKD patients presented with more comorbidities and more complex lesions when compared with the reference population. They experienced higher rate of adverse events at 1-year follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Graphic abstract<\/jats:title><\/jats:sec>","DOI":"10.1007\/s00392-019-01575-y","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T18:15:23Z","timestamp":1575310523000},"page":"845-856","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["One-year clinical outcomes in patients with renal insufficiency after contemporary PCI: data from a multicenter registry"],"prefix":"10.1007","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6567-2022","authenticated-orcid":false,"given":"Sean S.","family":"Scholz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Lauder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Ewen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saarraaken","family":"Kulenthiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orazbek","family":"Sakhov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris","family":"Kauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Witkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vaglimigli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Wijns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Scheller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Mahfoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,2]]},"reference":[{"key":"1575_CR1","unstructured":"United States Renal Data System (2015) URDS annual data report: Epidemiology of Kidney Disease in the United States. National Institute of Health, National Institute of Diabetes and Digestive Kidney Disease: 2015 https:\/\/www.usrds.org\/2017\/download\/2017_Volume_2_ESRD_in_the_US.pdf"},{"key":"1575_CR2","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.1093\/ndt\/gfp519","volume":"24","author":"A Kramer","year":"2009","unstructured":"Kramer A, Stel V, Zoccali C et al (2009) An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006. Nephrol Dial Transplant 24:3557\u20133566. https:\/\/doi.org\/10.1093\/ndt\/gfp519","journal-title":"Nephrol Dial Transplant"},{"key":"1575_CR3","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/S0140-6736(14)61601-9","volume":"385","author":"T Liyanage","year":"2015","unstructured":"Liyanage T, Ninomiya T, Jha V et al (2015) Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 385:1975\u20131982. https:\/\/doi.org\/10.1016\/S0140-6736(14)61601-9","journal-title":"Lancet"},{"key":"1575_CR4","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","volume":"382","author":"V Jha","year":"2013","unstructured":"Jha V, Garcia-Garcia G, Iseki K et al (2013) Chronic kidney disease: global dimension and perspectives. Lancet 382:260\u2013272. https:\/\/doi.org\/10.1016\/S0140-6736(13)60687-X","journal-title":"Lancet"},{"key":"1575_CR5","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1093\/aje\/kwn033","volume":"167","author":"BC Astor","year":"2008","unstructured":"Astor BC, Hallan SI, Miller ER et al (2008) Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol 167:1226\u20131234. https:\/\/doi.org\/10.1093\/aje\/kwn033","journal-title":"Am J Epidemiol"},{"key":"1575_CR6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/jcsm.12053","volume":"7","author":"S-M Ou","year":"2016","unstructured":"Ou S-M, Chen Y-T, Hung S-C et al (2016) Association of estimated glomerular filtration rate with all-cause and cardiovascular mortality: the role of malnutrition\u2013inflammation\u2013cachexia syndrome: eGFR with mortality and the role of MICS. J Cachexia Sarcopenia Muscle 7:144\u2013151. https:\/\/doi.org\/10.1002\/jcsm.12053","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1575_CR7","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D et al (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296\u20131305. https:\/\/doi.org\/10.1056\/NEJMoa041031","journal-title":"N Engl J Med"},{"key":"1575_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000473863","volume":"137","author":"NL Grandjean-Thomsen","year":"2017","unstructured":"Grandjean-Thomsen NL, Marley P, Shadbolt B, Farshid A (2017) Impact of mild-to-moderate chronic kidney disease on one year outcomes after percutaneous coronary intervention. Nephron 137:23\u201328. https:\/\/doi.org\/10.1159\/000473863","journal-title":"Nephron"},{"key":"1575_CR9","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1093\/qjmed\/hcl101","volume":"99","author":"NC Edwards","year":"2006","unstructured":"Edwards NC, Steeds RP, Ferro CJ, Townend JN (2006) The treatment of coronary artery disease in patients with chronic kidney disease. QJM 99:723\u2013736. https:\/\/doi.org\/10.1093\/qjmed\/hcl101","journal-title":"QJM"},{"key":"1575_CR10","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1161\/hy1001.096358","volume":"38","author":"J Blacher","year":"2001","unstructured":"Blacher J, Guerin AP, Pannier B et al (2001) Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38:938\u2013942. https:\/\/doi.org\/10.1161\/hy1001.096358","journal-title":"Hypertension"},{"key":"1575_CR11","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.jacc.2015.06.1334","volume":"66","author":"S Bangalore","year":"2015","unstructured":"Bangalore S, Guo Y, Samadashvili Z et al (2015) Revascularization in patients with multivessel coronary artery disease and chronic kidney disease. J Am Coll Cardiol 66:1209\u20131220. https:\/\/doi.org\/10.1016\/j.jacc.2015.06.1334","journal-title":"J Am Coll Cardiol"},{"key":"1575_CR12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1093\/ejcts\/ezs360","volume":"43","author":"H Zheng","year":"2013","unstructured":"Zheng H, Xue S, Lian F et al (2013) Meta-analysis of clinical studies comparing coronary artery bypass grafting with percutaneous coronary intervention in patients with end-stage renal disease. Eur J Cardiothorac Surg 43:459\u2013467. https:\/\/doi.org\/10.1093\/ejcts\/ezs360","journal-title":"Eur J Cardiothorac Surg"},{"key":"1575_CR13","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1681\/ASN.2016030345","volume":"27","author":"GR Shroff","year":"2016","unstructured":"Shroff GR, Herzog CA (2016) Coronary revascularization in patients with CKD stage 5D: pragmatic considerations. J Am Soc Nephrol 27:3521\u20133529. https:\/\/doi.org\/10.1681\/ASN.2016030345","journal-title":"J Am Soc Nephrol"},{"key":"1575_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijcard.2016.11.026","volume":"227","author":"NR Smilowitz","year":"2017","unstructured":"Smilowitz NR, Gupta N, Guo Y et al (2017) Management and outcomes of acute myocardial infarction in patients with chronic kidney disease. Int J Cardiol 227:1\u20137. https:\/\/doi.org\/10.1016\/j.ijcard.2016.11.026","journal-title":"Int J Cardiol"},{"key":"1575_CR15","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.jacc.2018.05.057","volume":"72","author":"G Giustino","year":"2018","unstructured":"Giustino G, Mehran R, Serruys PW et al (2018) Left main revascularization with PCI or CABG in patients with chronic kidney disease. J Am Coll Cardiol 72:754\u2013765. https:\/\/doi.org\/10.1016\/j.jacc.2018.05.057","journal-title":"J Am Coll Cardiol"},{"key":"1575_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.4244\/EIJ-D-17-00620","volume":"14","author":"M Milojevic","year":"2018","unstructured":"Milojevic M, Head SJ, Mack MJ et al (2018) The impact of chronic kidney disease on outcomes following percutaneous coronary intervention versus coronary artery bypass grafting in patients with complex coronary artery disease: five-year follow-up of the SYNTAX trial. EuroIntervention 14:102\u2013111. https:\/\/doi.org\/10.4244\/EIJ-D-17-00620","journal-title":"EuroIntervention"},{"key":"1575_CR17","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.ajkd.2006.05.021","volume":"48","author":"DE Weiner","year":"2006","unstructured":"Weiner DE, Tabatabai S, Tighiouart H et al (2006) Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. Am J Kidney Dis 48:392\u2013401. https:\/\/doi.org\/10.1053\/j.ajkd.2006.05.021","journal-title":"Am J Kidney Dis"},{"key":"1575_CR18","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1681\/ASN.V92267","volume":"9","author":"RN Foley","year":"1998","unstructured":"Foley RN, Parfrey PS, Sarnak MJ (1998) Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9:S16\u201323","journal-title":"J Am Soc Nephrol"},{"key":"1575_CR19","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1002\/sim.2174","volume":"24","author":"J Xie","year":"2005","unstructured":"Xie J, Liu C (2005) Adjusted Kaplan\u2013Meier estimator and log-rank test with inverse probability of treatment weighting for survival data. Stat Med 24:3089\u20133110. https:\/\/doi.org\/10.1002\/sim.2174","journal-title":"Stat Med"},{"key":"1575_CR20","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1016\/j.jacc.2014.01.017","volume":"63","author":"MV Madhavan","year":"2014","unstructured":"Madhavan MV, Tarigopula M, Mintz GS et al (2014) Coronary artery calcification. J Am Coll Cardiol 63:1703\u20131714. https:\/\/doi.org\/10.1016\/j.jacc.2014.01.017","journal-title":"J Am Coll Cardiol"},{"key":"1575_CR21","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.1093\/eurheartj\/ehw453","volume":"37","author":"F Alfonso","year":"2016","unstructured":"Alfonso F, Rivero F (2016) Coronary revascularization in diabetic patients with chronic kidney disease. Eur Heart J 37:3448\u20133451. https:\/\/doi.org\/10.1093\/eurheartj\/ehw453","journal-title":"Eur Heart J"},{"key":"1575_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/ccd.22613","volume":"77","author":"S Bangalore","year":"2011","unstructured":"Bangalore S, Vlachos HA, Selzer F et al (2011) Percutaneous coronary intervention of moderate to severe calcified coronary lesions: Insights from the National Heart, Lung, and Blood Institute Dynamic Registry. Catheter Cardiovasc Interv 77:22\u201328. https:\/\/doi.org\/10.1002\/ccd.22613","journal-title":"Catheter Cardiovasc Interv"},{"key":"1575_CR23","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/j.jacc.2011.06.056","volume":"58","author":"TT Tsai","year":"2011","unstructured":"Tsai TT, Messenger JC, Brennan JM et al (2011) Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease. J Am Coll Cardiol 58:1859\u20131869. https:\/\/doi.org\/10.1016\/j.jacc.2011.06.056","journal-title":"J Am Coll Cardiol"},{"key":"1575_CR24","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/j.jcin.2016.06.051","volume":"9","author":"JM Lee","year":"2016","unstructured":"Lee JM, Kang J, Lee E et al (2016) Chronic kidney disease in the second-generation drug-eluting stent era. J Am Coll Cardiol Intv 9:2097\u20132109. https:\/\/doi.org\/10.1016\/j.jcin.2016.06.051","journal-title":"J Am Coll Cardiol Intv"},{"key":"1575_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jcin.2008.06.012","volume":"2","author":"F Latif","year":"2009","unstructured":"Latif F, Kleiman NS, Cohen DJ et al (2009) In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents. JACC Cardiovasc Interv 2:37\u201345. https:\/\/doi.org\/10.1016\/j.jcin.2008.06.012","journal-title":"JACC Cardiovasc Interv"},{"key":"1575_CR26","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1016\/j.jcin.2018.04.038","volume":"11","author":"RJ de Winter","year":"2018","unstructured":"de Winter RJ, Chandrasekhar J, Kalkman DN et al (2018) 1-year clinical outcomes of all-comer patients treated with the dual-therapy COMBO stent. JACC Cardiovasc Interv 11:1969\u20131978. https:\/\/doi.org\/10.1016\/j.jcin.2018.04.038","journal-title":"JACC Cardiovasc Interv"},{"key":"1575_CR27","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(13)62037-1","volume":"383","author":"C von Birgelen","year":"2014","unstructured":"von Birgelen C, Sen H, Lam MK et al (2014) Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial. Lancet 383:413\u2013423. https:\/\/doi.org\/10.1016\/S0140-6736(13)62037-1","journal-title":"Lancet"},{"key":"1575_CR28","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jjcc.2018.12.009","volume":"73","author":"A Shimizu","year":"2019","unstructured":"Shimizu A, Sonoda S, Muraoka Y et al (2019) Bleeding and ischemic events during dual antiplatelet therapy after second-generation drug-eluting stent implantation in hemodialysis patients. J Cardiol 73:470\u2013478. https:\/\/doi.org\/10.1016\/j.jjcc.2018.12.009","journal-title":"J Cardiol"},{"key":"1575_CR29","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.jcin.2012.02.014","volume":"5","author":"SS Naidu","year":"2012","unstructured":"Naidu SS, Krucoff MW, Rutledge DR et al (2012) Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation. J Am Coll Cardiol Intv 5:626\u2013635. https:\/\/doi.org\/10.1016\/j.jcin.2012.02.014","journal-title":"J Am Coll Cardiol Intv"},{"key":"1575_CR30","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003990","author":"R Lu","year":"2016","unstructured":"Lu R, Tang F, Zhang Y et al (2016) Comparison of drug-eluting and bare metal stents in patients with chronic kidney disease: an updated systematic review and meta-analysis. JAHA. https:\/\/doi.org\/10.1161\/JAHA.116.003990","journal-title":"JAHA"},{"key":"1575_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s00392-018-1260-0","volume":"107","author":"N Marx","year":"2018","unstructured":"Marx N, Noels H, Jankowski J et al (2018) Mechanisms of cardiovascular complications in chronic kidney disease: research focus of the Transregional Research Consortium SFB TRR219 of the University Hospital Aachen (RWTH) and the Saarland University. Clin Res Cardiol 107:120\u2013126. https:\/\/doi.org\/10.1007\/s00392-018-1260-0","journal-title":"Clin Res Cardiol"},{"key":"1575_CR32","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s00392-011-0347-7","volume":"100","author":"E Kaya","year":"2011","unstructured":"Kaya E, Cuneo A, Hochadel M et al (2011) Impact of chronic kidney disease on the prognosis of patients undergoing percutaneous coronary interventions using drug-eluting stents. Clin Res Cardiol 100:1103\u20131109. https:\/\/doi.org\/10.1007\/s00392-011-0347-7","journal-title":"Clin Res Cardiol"},{"key":"1575_CR33","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1681\/ASN.2016030336","volume":"28","author":"K Schuett","year":"2017","unstructured":"Schuett K, Savvaidis A, Maxeiner S et al (2017) Clot structure: a potent mortality risk factor in patients on hemodialysis. J Am Soc Nephrol 28:1622\u20131630. https:\/\/doi.org\/10.1681\/ASN.2016030336","journal-title":"J Am Soc Nephrol"}],"updated-by":[{"DOI":"10.1007\/s00392-020-01600-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000}}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-019-01575-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00392-019-01575-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-019-01575-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T11:58:28Z","timestamp":1665143908000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00392-019-01575-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,2]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1575"],"URL":"https:\/\/doi.org\/10.1007\/s00392-019-01575-y","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00392-020-01600-5","asserted-by":"object"}]},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,2]]},"assertion":[{"value":"7 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this article unfortunately contained a mistake. The given name and family name of the fourth author Saaraaken Kulenthiran were switched in the original publication.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"FM and SE have received scientific support and speaker honoraria from Medtronic and ReCor Medical. NM has received support for clinical trial leadership from Boehringer Ingelheim and Novo Nordisk and served as a consultant to Boehringer Ingelheim, Merck, Novo Nordisk, AstraZeneca, BMS, received grant support from Boehringer Ingelheim, and served as a speaker for Boehringer Ingelheim, Merck, Novo Nordisk, Lilly, BMS, and Astra Zeneca. NM declines all personal compensation from pharma or device companies. The remaining authors have no disclosures to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}